Am­gen bets on stem cell com­pa­ny For­tu­na Fix in $25M round

Am­gen’s ven­ture arm just made a bet on re­gen­er­a­tive med­i­cine for the first time. The phar­ma gi­ant pitched in to a new $25 mil­lion fi­nanc­ing round for Cana­di­an stem cell com­pa­ny For­tu­na Fix.

For­tu­na is work­ing on new ways to re­grow neur­al tis­sue dam­aged by de­gen­er­a­tion and trau­ma. With its tech­nol­o­gy, the com­pa­ny hopes to mim­ic the ca­pa­bil­i­ties of the Mex­i­can sala­man­der, known for its abil­i­ty to re­grow its own spinal cord, jaw, tail, skin and limbs — all with­out scar­ring.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.